Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
7 hedge funds and large institutions have $624K invested in Avenue Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
21% less capital invested
Capital invested by funds: $789K → $624K (-$165K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$8.21K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$4.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$8.21K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.11K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $279K | -$4.11K | -1 | -1% |
|
|
BRWA
2
B. Riley Wealth Advisors
Boca Raton,
Florida
| $179K | +$8.21K | +2 | +4% |
|
|
FWM
3
Frontier Wealth Management
Kansas City,
Missouri
| $56K | – | – | – |
|
4
BlackRock
New York
| $52K | – | – | – |
|
|
GPCM
5
Granite Point Capital Management
Boston,
Massachusetts
| $49K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $7K | -$8.21K | -2 | -50% |
|
|
7
Bank of America
Charlotte,
North Carolina
| $2K | +$4.11K | +1 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| – | -$2K | -1 | Closed |
|
ATXI Hedge Fund Activity: Q3 2018 in Review
7 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q3 2018, worth a combined $624K — down 21% from $789K a quarter earlier.
Fund positioning in ATXI was balanced in Q3 2018: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was B. Riley Wealth Advisors, adding an estimated $8.21K. The largest seller was UBS Group, cutting an estimated $8.21K.
- 7 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $624K of Avenue Therapeutics, Inc. Common Stock stock for Q3 2018, down 21% quarter-over-quarter.
- 1 fund opened new Avenue Therapeutics, Inc. Common Stock positions in Q3 2018 and 1 closed out, a net change of 0 holders.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q3 2018 was B. Riley Wealth Advisors, an estimated $8.21K added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q3 2018 was UBS Group, an estimated $8.21K sold.
Based on aggregated 13F filings for Q3 2018.